Equillium, Inc. (NASDAQ:EQ) Short Interest Up 666.5% in August

Key Points

• Equillium, Inc. experienced a massive increase in short interest of 666.5% in August, rising from 427,900 shares to a total of 3,280,000 shares.
• The company's stock price declined by 10.1% recently, trading at $1.57, with a twelve-month low of $0.27 and a high of $2.26.
• Equillium reported a quarterly loss of ($0.16) earnings per share, missing the consensus estimate by $0.02, and has a negative return on equity of 139.56%.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 3,280,000 shares, anincreaseof666.5% from the July 31st total of 427,900 shares. Based on an average trading volume of 7,930,000 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 7,930,000 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Equillium to a "sell" rating in a research note on Friday. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $1.00.

Equillium Price Performance

EQ traded up $0.16 on Friday, hitting $1.91. The company had a trading volume of 7,303,730 shares, compared to its average volume of 15,650,398. Equillium has a 52-week low of $0.27 and a 52-week high of $2.35. The stock has a fifty day simple moving average of $0.85 and a 200-day simple moving average of $0.63. The firm has a market capitalization of $113.65 million, a P/E ratio of -3.41 and a beta of 1.58.

Equillium (NASDAQ:EQ - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equillium had a negative return on equity of 139.56% and a negative net margin of 19.62%. Equities research analysts expect that Equillium will post 0.14 earnings per share for the current fiscal year.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.